2.30
-0.1(-4.17%)
Currency In USD
| Previous Close | 2.4 |
| Open | 2.38 |
| Day High | 2.39 |
| Day Low | 2.28 |
| 52-Week High | 3.22 |
| 52-Week Low | 0.51 |
| Volume | 147,947 |
| Average Volume | 299,478 |
| Market Cap | 129.58M |
| PE | -2.91 |
| EPS | -0.79 |
| Moving Average 50 Days | 2.36 |
| Moving Average 200 Days | 2.18 |
| Change | -0.1 |
If you invested $1000 in Spero Therapeutics, Inc. (SPRO) since IPO date, it would be worth $200 as of February 21, 2026 at a share price of $2.3. Whereas If you bought $1000 worth of Spero Therapeutics, Inc. (SPRO) shares 5 years ago, it would be worth $116.63 as of February 21, 2026 at a share price of $2.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
GlobeNewswire Inc.
Dec 19, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacteria
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 28, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacteria
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
GlobeNewswire Inc.
Nov 04, 2025 9:05 PM GMT
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacteri